Consulting

Incorrect prediction of a compound’s pharmacokinetic profile combined with an incomplete understanding of its efficacy and safety is the leading cause for drug attrition in late preclinical and clinical phases. To enhance the predictive power of your preclinical PKPD studies, an elegant experimental state-of-the art design with a vast number of control conditions is required to minimize the influence of assay biases.

Having more than fourteen years academic and industrial experience with both in vitro and in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies I am here to assist you with your experimental design, study coordination, and evaluation of the data. To do so, I have access to a global network of research institutes, key opinion leaders (KOLs) and contract research organizations (CROs) which can be involved.

Besides my knowledge as an European registered toxicologist (EUROTOX) and pharmacologist (EPHAR), I also have a strong background in biochemical and cellular biology, and the use of systems biology (i.e., iterations of in silico and in vitro approaches). Using these approaches, I can assist you to get enhanced insights into your compound’s mechanism of action (MOA) by a deeper understanding of their on- and off-targets (toxico- and pharmacodynamics).

Thereby, my vast preclinical experience in PKPD area allows for the support needed to bring your product forward at a faster pace, with higher quality outcomes, in a cost-effective way to maximize the potency of your compounds for clinical development.​